Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Walter Quan, Jr., MD Chief of Medical Oncology and Director of Immunotherapy at Cancer Treatment Centers of America- Western Regional Medical Center is presenting new findings that are showing a major benefit to cancer patients.

11 Nov 2013

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing.

12 Jul 2013

Report: 83% of cancer doctors face oncology drug shortages

Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510).

4 Jun 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

Tumor texture analysis has prognostic potential

Tumor texture analysis, determined by computed tomography, holds promise as a prognostic biomarker in patients with esophageal cancer, research indicates.

15 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

What did Pope John Paul II, Ronald Reagan and Robin Gibb of the Bee Gees have in common? Each was diagnosed with colorectal cancer, the third most commonly diagnosed cancer in the world and the fourth most common cause of cancer death.

29 Jan 2013

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for people with metastatic colorectal cancer (mCRC).

23 Jan 2013

Oxaliplatin and bevacizumab disappoint for rectal cancer

The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results.

9 Jan 2013

Combining 5-fluorouracil and IL-1 beta inhibitor can improve effectiveness of chemotherapy

These results reveal how the immune system can then limit the effectiveness of some cancer chemotherapies. The researchers now intend to block the molecules responsible for negative immune system activation to increase the efficiency of chemotherapy. A clinical trial to test this hypothesis should begin very soon.

5 Dec 2012

Bevacizumab ruled out for stage III colorectal cancer

Findings from the AVANT trial do not support the use of bevacizumab in patients receiving oxaliplatin-based chemotherapy for resected stage III or high-risk stage II colon carcinoma.

19 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

FoXTROT results: preoperative chemo could become new standard

Preoperative chemotherapy is a feasible option for resectable advanced colon cancer, show results of the FoXTROT trial.

1 Nov 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

Fluorouracil News and Research

New drug combination therapy effective for patients with HER2-positive breast cancer

CTCA doctor presents cutting-edge treatments for cancer patients to medical colleagues

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

Report: 83% of cancer doctors face oncology drug shortages

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Tumor texture analysis has prognostic potential

Regeneron fourth quarter total revenues increase to $415 million

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

Genentech receives FDA approval for new use of Avastin plus chemotherapy to treat mCRC

Oxaliplatin and bevacizumab disappoint for rectal cancer

Combining 5-fluorouracil and IL-1 beta inhibitor can improve effectiveness of chemotherapy

Bevacizumab ruled out for stage III colorectal cancer

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

FoXTROT results: preoperative chemo could become new standard

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

Combination chemotherapy confirmed viable for penile cancer

Study examines whether eribulin offers added benefit to women with breast cancer

Healthcare professionals receive SingHealth Duke-NUS Scientific Congress abstract awards

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News